Predicting the Potential for Cannabinoids to Precipitate Pharmacokinetic Drug Interactions via Reversible Inhibition or Inactivation of Major Cytochromes P450

• Published in: Drug metabolism and disposition Vol. 48; no. 10; pp. 1008 - 1017
• Main Authors: Bansal, Sumit, Maharao, Neha, Paine, Mary F., Unadkat, Jashvant D.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2020; The American Society for Pharmacology and Experimental Therapeutics
• Subjects: Administration, Oral; Adult; Cannabidiol - administration & dosage; Cannabidiol - pharmacokinetics; Cytochrome P-450 Enzyme Inhibitors - administration & dosage; Cytochrome P-450 Enzyme Inhibitors - pharmacokinetics; Cytochrome P-450 Enzyme System - metabolism; Dronabinol - administration & dosage; Dronabinol - pharmacokinetics; Drug Evaluation, Preclinical; Drug Interactions; Humans; Inhibitory Concentration 50; Microsomes, Liver; Special Section on Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions; G6P; FDA; CBD; HLM; PBPK; FaSSIF; THC; 11-OH-THC; AUC; BSA; LC-MS/MS; COOH-THC; FeSSIF; UPLC; TDI; CYP; AUCR
• DOI: 10.1124/dmd.120.000073
• ISSN: 0090-9556; 1521-009X

Cannabis is used for both recreational and medicinal purposes. The most abundant constituents are the cannabinoids - cannabidiol (CBD, nonpsychoactive) and (−)-trans-Δ9-tetrahydrocannabinol (THC, psychoactive). Both have been reported to reversibly inhibit or inactivate cytochrome P450 (CYPs) enzymes. However, the low aqueous solubility, microsomal protein binding, and nonspecific binding to labware were not considered, potentially leading to an underestimation of CYPs inhibition potency. Therefore, the binding-corrected reversible (IC50,u) and irreversible (KI,u) inhibition potency of each cannabinoid toward major CYPs were determined. The fraction unbound of CBD and THC in the incubation mixture was 0.12 ± 0.04 and 0.05 ± 0.02, respectively. The IC50,u for CBD toward CYP1A2, 2C9, 2C19, 2D6, and 3A was 0.45 ± 0.17, 0.17 ± 0.03, 0.30 ± 0.06, 0.95 ± 0.50, and 0.38 ± 0.11 µM, respectively; the IC50,u for THC was 0.06 ± 0.02, 0.012 ± 0.001, 0.57 ± 0.22, 1.28 ± 0.25, and 1.30 ± 0.34 µM, respectively. Only CBD showed time-dependent inactivation (TDI) of CYP1A2, 2C19, and CYP3A, with inactivation efficiencies (kinact/KI,u) of 0.70 ± 0.34, 0.11 ± 0.06, and 0.14 ± 0.04 minutes−1 µM−1, respectively. A combined (reversible inhibition and TDI) mechanistic static model populated with these data predicted a moderate to strong pharmacokinetic interaction risk between orally administered CBD and drugs extensively metabolized by CYP1A2/2C9/2C19/2D6/3A and between orally administered THC and drugs extensively metabolized by CYP1A2/2C9/3A. These predictions will be extended to a dynamic model using physiologically based pharmacokinetic modeling and simulation and verified with a well-designed clinical cannabinoid-drug interaction study. This study is the first to consider the impact of limited aqueous solubility, nonspecific binding to labware, or extensive binding to incubation protein shown by cannabidiol (CBD) and delta-9-tetrahydrocannabinol (THC) on their true cytochrome P450 inhibitory potency. A combined mechanistic static model predicted a moderate to strong pharmacokinetic interaction risk between orally administered CBD and drugs extensively metabolized by CYP1A2, 2C9, 2C19, 2D6, or 3A and between orally administered THC and drugs extensively metabolized by CYP1A2, 2C9, or 3A.